194 related articles for article (PubMed ID: 18472962)
1. Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.
Junk DJ; Vrba L; Watts GS; Oshiro MM; Martinez JD; Futscher BW
Neoplasia; 2008 May; 10(5):450-61. PubMed ID: 18472962
[TBL] [Abstract][Full Text] [Related]
2. p53 regulates FAK expression in human tumor cells.
Golubovskaya VM; Finch R; Kweh F; Massoll NA; Campbell-Thompson M; Wallace MR; Cance WG
Mol Carcinog; 2008 May; 47(5):373-82. PubMed ID: 17999388
[TBL] [Abstract][Full Text] [Related]
3. p53-dependent down-regulation of telomerase is mediated by p21waf1.
Shats I; Milyavsky M; Tang X; Stambolsky P; Erez N; Brosh R; Kogan I; Braunstein I; Tzukerman M; Ginsberg D; Rotter V
J Biol Chem; 2004 Dec; 279(49):50976-85. PubMed ID: 15371422
[TBL] [Abstract][Full Text] [Related]
4. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.
Cao Y; Gao Q; Wazer DE; Band V
Cancer Res; 1997 Dec; 57(24):5584-9. PubMed ID: 9407971
[TBL] [Abstract][Full Text] [Related]
5. Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line.
Jiang W; Wang XW; Unger T; Forgues M; Kim JW; Hussain SP; Bowman E; Spillare EA; Lipsky MM; Meck JM; Cavalli LR; Haddad BR; Harris CC
Int J Cancer; 2010 Sep; 127(5):1011-20. PubMed ID: 20017137
[TBL] [Abstract][Full Text] [Related]
6. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
[TBL] [Abstract][Full Text] [Related]
7. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2.
Dhar G; Banerjee S; Dhar K; Tawfik O; Mayo MS; Vanveldhuizen PJ; Banerjee SK
Cancer Res; 2008 Jun; 68(12):4580-7. PubMed ID: 18559502
[TBL] [Abstract][Full Text] [Related]
8. p53 induces distinct epigenetic states at its direct target promoters.
Vrba L; Junk DJ; Novak P; Futscher BW
BMC Genomics; 2008 Oct; 9():486. PubMed ID: 18922183
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53-induced immortalization of primary human mammary epithelial cells.
Gao Q; Hauser SH; Liu XL; Wazer DE; Madoc-Jones H; Band V
Cancer Res; 1996 Jul; 56(13):3129-33. PubMed ID: 8674072
[TBL] [Abstract][Full Text] [Related]
10. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.
Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS
PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093
[TBL] [Abstract][Full Text] [Related]
11. p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines.
Anaganti S; Fernández-Cuesta L; Langerød A; Hainaut P; Olivier M
Cancer Lett; 2011 Jan; 300(2):215-24. PubMed ID: 21071137
[TBL] [Abstract][Full Text] [Related]
12. Toca-1 is suppressed by p53 to limit breast cancer cell invasion and tumor metastasis.
Chander H; Brien CD; Truesdell P; Watt K; Meens J; Schick C; Germain D; Craig AW
Breast Cancer Res; 2014 Dec; 16(6):3413. PubMed ID: 25547174
[TBL] [Abstract][Full Text] [Related]
13. Role of human HGFIN/nmb in breast cancer.
Metz RL; Patel PS; Hameed M; Bryan M; Rameshwar P
Breast Cancer Res; 2007; 9(5):R58. PubMed ID: 17845721
[TBL] [Abstract][Full Text] [Related]
14. TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor.
Spiesbach K; Tannapfel A; Mössner J; Engeland K
Int J Cancer; 2005 Apr; 114(4):555-62. PubMed ID: 15578720
[TBL] [Abstract][Full Text] [Related]
15. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
16. The involvement of HER2 and p53 status in the regulation of telomerase in irradiated breast cancer cells.
Papanikolaou V; Iliopoulos D; Dimou I; Dubos S; Tsougos I; Theodorou K; Kitsiou-Tzeli S; Tsezou A
Int J Oncol; 2009 Nov; 35(5):1141-9. PubMed ID: 19787269
[TBL] [Abstract][Full Text] [Related]
17. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.
Mirza A; McGuirk M; Hockenberry TN; Wu Q; Ashar H; Black S; Wen SF; Wang L; Kirschmeier P; Bishop WR; Nielsen LL; Pickett CB; Liu S
Oncogene; 2002 Apr; 21(17):2613-22. PubMed ID: 11965534
[TBL] [Abstract][Full Text] [Related]
18. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.
Yan W; Liu G; Scoumanne A; Chen X
Cancer Res; 2008 Aug; 68(16):6789-96. PubMed ID: 18701504
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription.
Kanaya T; Kyo S; Hamada K; Takakura M; Kitagawa Y; Harada H; Inoue M
Clin Cancer Res; 2000 Apr; 6(4):1239-47. PubMed ID: 10778946
[TBL] [Abstract][Full Text] [Related]
20. p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma.
Sood AK; Coffin J; Jabbari S; Buller RE; Hendrix MJ; Klingelhutz A
Cancer Biol Ther; 2002; 1(5):511-7. PubMed ID: 12496479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
